Proactive Investors - Run By Investors For Investors

First data for Redx Pharma’s RXC006 fibrosis candidate shows compound has “great potential”

The data showed RXC006 was able to suppress the Wnt pathway, which is widely believed to be heavily involved in the scarring process associated with lung fibrosis
fibrosis
Along with cancer, fibrosis is one of Redx’s core focus areas

The first pre-clinical data for Redx Pharma Plc’s (LON:REDX) RXC006 drug candidate has suggested that the compound has “great potential” as a fibrosis treatment.

RXC006 is what’s known as a Porcupine inhibitor. They work by dialling down the Porcupine protein, which is the control switch for the Wnt pathway – widely believed to be heavily involved in the scarring process in the lung typical of idiopathic pulmonary fibrosis.

READ: Redx hails new fibrosis candidate

This first batch of in-vivo data showed that the compound was “highly effective” in suppressing the Wnt pathway and lung fibrosis.

Suppression of both liver and kidney fibrosis has also been shown in animal models.

“The data suggests that RXC006 has great potential to treat fibrosis in human patients,” said chief scientific officer Richard Amer.

“Redx are progressing RXC006 towards the clinic for the treatment of Idiopathic Pulmonary Fibrosis and plan to initiate first in man clinical trials during 2020.”

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

Alliance
April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.
1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
scientist in lab
February 26 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use